Page last updated: 2024-08-17

quinoxalines and tx 402

quinoxalines has been researched along with tx 402 in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (80.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hori, H; Kinashi, Y; Masunaga, S; Nagasawa, H; Nagata, K; Ohnishi, K; Ohnishi, T; Ono, K; Suzuki, M; Takahashi, A; Uto, Y1
Hori, H; Kinashi, Y; Masunaga, S; Nagasawa, H; Nagata, K; Ono, K; Suzuki, M; Uto, Y1
Hori, H; Kinashi, Y; Maruhashi, A; Masunaga, S; Nagasawa, H; Nagata, K; Ono, K; Sakurai, Y; Suzuki, M; Uto, Y1
Hori, H; Ide, T; Kitajima, Y; Miyazaki, K; Miyoshi, A; Nagasawa, H; Ohtaka, K; Uto, Y1
Morishige, K; Nagasawa, H; Nozawa-Suzuki, N; Ohnishi, K1

Other Studies

5 other study(ies) available for quinoxalines and tx 402

ArticleYear
Combination of the antivascular agent ZD6126 with hypoxic cytotoxin treatment, with reference to the effect on quiescent tumor cells and the dependency on p53 status of tumor cells.
    Oncology reports, 2005, Volume: 14, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Cyclic N-Oxides; Gamma Rays; Head and Neck Neoplasms; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Micronucleus Tests; Mutation; Organophosphorus Compounds; Quinoxalines; Radiotherapy; Tirapazamine; Triazines; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2005
The usefulness of continuous administration of hypoxic cytotoxin combined with mild temperature hyperthermia, with reference to effects on quiescent tumour cell populations.
    International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2005, Volume: 21, Issue:4

    Topics: Animals; Antineoplastic Agents; Bromodeoxyuridine; Carcinoma, Squamous Cell; Combined Modality Therapy; Cyclic N-Oxides; Female; Fluorescent Antibody Technique; Hyperthermia, Induced; Mice; Mice, Inbred C3H; Micronucleus Tests; Neoplasm Transplantation; Neoplasms; Quinoxalines; Tirapazamine; Triazines

2005
The usefulness of mild temperature hyperthermia combined with a newly developed hypoxia-oriented 10B conjugate compound, TX-2100, for boron neutron capture therapy.
    International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2006, Volume: 22, Issue:4

    Topics: Animals; Borohydrides; Boron Compounds; Boron Neutron Capture Therapy; Carcinoma, Squamous Cell; Cell Proliferation; Cell Survival; Combined Modality Therapy; Cyclic N-Oxides; Female; Fluorescent Antibody Technique; Hyperthermia, Induced; Hypoxia; Mice; Mice, Inbred C3H; Micronucleus Tests; Quinoxalines; Quinuclidines; Sulfhydryl Compounds; Time Factors; Tissue Distribution; Tumor Cells, Cultured

2006
Hypoxia accelerates cancer invasion of hepatoma cells by upregulating MMP expression in an HIF-1alpha-independent manner.
    International journal of oncology, 2006, Volume: 29, Issue:6

    Topics: Carcinoma, Hepatocellular; Cell Growth Processes; Cell Hypoxia; Cell Movement; Cyclic N-Oxides; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Matrix Metalloproteinases; Neoplasm Invasiveness; Proto-Oncogene Protein c-ets-1; Quinoxalines; Reverse Transcriptase Polymerase Chain Reaction; Transfection; Up-Regulation

2006
The inhibitory effect of hypoxic cytotoxin on the expansion of cancer stem cells in ovarian cancer.
    Biochemical and biophysical research communications, 2015, Feb-20, Volume: 457, Issue:4

    Topics: Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cyclic N-Oxides; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Neoplastic Stem Cells; Octamer Transcription Factor-3; Ovarian Neoplasms; Ovary; Quinoxalines

2015